Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	5.37
Equity-to-Asset	0.54
Debt-to-Equity	0.06
Debt-to-EBITDA	0.3
Interest Coverage	5.09
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	17.66	Distress Grey Safe
Beneish M-Score	-0.61	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	342.2
	3-Year FCF Growth Rate	89.8
	3-Year Book Growth Rate	17.7
	Future 3-5Y EPS without NRI Growth Rate Estimate	192.16
	Future 3-5Y Total Revenue Growth Rate Estimate	37.84

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	45.93
	9-Day RSI	51.96
	14-Day RSI	54.74

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.99
	Quick Ratio	0.87
	Cash Ratio	0.46
	Days Inventory	31.66
	Days Sales Outstanding	41.05
	Days Payable	91.68

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-4.9
	Shareholder Yield %	-0.17

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	63.38
	Operating Margin %	12.49
	Net Margin %	7.72
	FCF Margin %	3.35
	ROE %	23.46
	ROA %	10.14
	ROIC %	21.54
	3-Year ROIIC %	64.16
	ROC (Joel Greenblatt) %	214.69
	ROCE %	22
	Years of Profitability over Past 10-Year	1

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	141.68
	Forward PE Ratio	86.72
	PE Ratio without NRI	141.68
	Price-to-Owner-Earnings	1005.24
	PS Ratio	10.95
	PB Ratio	17.46
	Price-to-Tangible-Book	1309.5
	Price-to-Free-Cash-Flow	335.08
	Price-to-Operating-Cash-Flow	142.64
	EV-to-EBIT	107.17
	EV-to-EBITDA	96.53
	EV-to-Revenue	11.06
	EV-to-FCF	327.08
	Price-to-Graham-Number	100.73
	Earnings Yield (Greenblatt) %	0.93
	FCF Yield %	0.3

GF Value: €343.95

FRA:T3X

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with T3X. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.